Effect of intranasal administration of Orexine A [GSK 649868] on IL [interleukin]-6-system, sleep-wake-regulation and and neurocognition (NARKOREX).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Apr 2009
At a glance
- Drugs GSK 649868 (Primary)
- Indications Narcolepsy
- Focus Therapeutic Use
- Acronyms NARKOREX
- 08 Apr 2009 Planned end date changed from 1 Jun 2008 to 1 Aug 2009 as reported by ClinicalTrials.gov.
- 08 Apr 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 04 Aug 2007 New trial record.